$GILD

AI 分析

生成於 May 11, 2026

AI Score
72/ 100
Hold$GILD

Gilead Sciences

$GILDNASDAQHealthcareLarge-Cap

Gilead develops and commercializes antiviral therapies including HIV, hepatitis, and COVID-19 treatments.

Market Cap
$108.0B
Revenue (TTM)
$27.8B
+5.0%
Net Income (TTM)
$5.5B
+10.0%
EPS (TTM)
$4.40
P/E Ratio
22.0
Dividend Yield
3.2%
52-Week Range
$65-$95
Beta
0.52
Dimension Scores
Fundamental
74
Technical
66
Sentiment
70
Risk / Reward
76
Momentum
62
FundTechSentRiskMome
Financial Health
Profitability
79strong
Growth
65moderate
Liquidity
84strong
Solvency
76strong
Efficiency
72strong

Valuation, technical analysis, investment thesis, risk assessment and more for $GILD

Free · No credit card required

免責聲明: AI 生成的分析僅供教育參考,不構成投資建議。請始終諮詢合格的理財顧問。

探索更多

用 AI 分析任意股票

獲取涵蓋基本面、技術面、情緒面、風險評估和投資論點的結構化研究報告——約 60 秒完成。